Le varianti antigeniche del parvovir us del cane tipo 2 (CPV-2) tra presente e futuro della profilassi vaccinale
Cavalli A., Martella V., Desario C., Camero M., Bellacicco A.L., De Palo P., Decaro N., Elia G., Buonavoglia C.
Dipartimento di Sanità Pubblica e Zootecnica, Facoltà di Medicina Veterinaria, Universitàdegli Studi di Bari
The antigenic relationships among the original canine parvovirus type 2 (CPV-2) and the variants CPV-2a, CPV-2b and CPV-2c were evaluated by hemagglutination-inhibition (HI) and sero-neutralization (SN) using the sera of immune dogs and rabbits. Marked differences between the homologous and heterologous antibody titres were appreciated only when using SN.
Dogs inoculated with CPV-2, which is still largely employed in vaccine formulations, developed relatively low SN antibody titres against the variants CPV-2a, CPV-2b and CPV-2c. These results were confirmed by cross-neutralization assays with mono-specific sera raised in immunized rabbits.
The results suggest that the vaccines based on the original type-2 of CPV are not able to elicit a strong protection against the new variants and that the vaccines should be updated taking into account the current epidemiology of CPV-2.
canine parvovirus, antigenic variants, protection